Skip to content

Study · Randomized controlled trial · n = 40 · 2007

5 results

Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis.

Tafazal SI, Ng L, Sell P

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society25 Jul 2006Cited by 32 (Europe PMC)

PMID16865379 (opens in a new tab)PMCIDPMC2200683 (opens in a new tab)DOI10.1007/s00586-006-0154-4 (opens in a new tab)PepBankPUB-16865379
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with lumbar spinal stenosis, ODI change was 1.3 points with salmon calcitonin versus 0.6 with placebo (P = 0.51).

    In plain wordsIn patients with spinal stenosis, disability change did not differ significantly between salmon calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeODI at 4 weeks
    Study

    n = 40

    Comparator
    Placebo nasal spray
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · nasal · 4 weeksAs given in this study (human).

    Measurements

    ODI change
    1.3 points
    calcitonin
    ODI change
    0.6 points
    placebo
    P value
    0.51
    between groups

    Source sentences

    Summary
    The change in ODI was a mean 1.3 points for the calcitonin group and 0.6 points for the placebo group (P = 0.51),
    1 context sentence
    Summary · context
    Forty patients with symptoms of neurogenic claudication and MRI proven lumbar spinal stenosis were randomly assigned either nasal salmon calcitonin or placebo nasal spray to use for 4 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with lumbar spinal stenosis, leg pain score change was 10 mm with salmon calcitonin versus 0 mm with placebo (P = 0.51).

    In plain wordsIn patients with spinal stenosis, leg pain change did not differ significantly between salmon calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeLeg pain VAS at 4 weeks
    Study

    n = 40

    Comparator
    Placebo nasal spray
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated · nasal · 4 weeksAs given in this study (human).

    Measurements

    Leg pain VAS change
    10 mm
    calcitonin
    Leg pain VAS change
    0 mm
    placebo
    P value
    0.51
    between groups

    Source sentences

    Summary
    the mean change in visual analogue score for leg pain was 10 mm in the calcitonin group and 0 mm in the placebo group (P = 0.51).
    1 context sentence
    Summary · context
    Forty patients with symptoms of neurogenic claudication and MRI proven lumbar spinal stenosis were randomly assigned either nasal salmon calcitonin or placebo nasal spray to use for 4 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with lumbar spinal stenosis, walking distance improved by 21 m with salmon calcitonin versus 8 m with placebo (P = 0.78).

    In plain wordsIn patients with spinal stenosis, walking distance change did not differ significantly between salmon calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeWalking distance at 4 weeks
    Study

    n = 40

    Comparator
    Placebo nasal spray
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · nasal · 4 weeksAs given in this study (human).

    Measurements

    Walking improvement
    21 m
    calcitonin
    Walking improvement
    8 m
    placebo
    P value
    0.78
    between groups

    Source sentences

    Summary
    There was no significant difference in walking distance between the two groups, with a mean improvement in walking distance of 21 m in the calcitonin group and 8 m in the placebo group (P = 0.78).
    1 context sentence
    Summary · context
    Forty patients with symptoms of neurogenic claudication and MRI proven lumbar spinal stenosis were randomly assigned either nasal salmon calcitonin or placebo nasal spray to use for 4 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with lumbar spinal stenosis, low back outcome scores did not differ significantly between salmon calcitonin and placebo at 4 weeks.

    In plain wordsIn patients with spinal stenosis, low back outcome scores did not differ significantly between salmon calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeLow back outcome score at 4 weeks
    Study

    n = 40

    Comparator
    Placebo nasal spray
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · nasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    At 4 weeks post treatment there was no statistically significant difference in the outcome measures between the two groups.
    2 context sentences
    Summary · context
    Standard spine outcome measures including Oswestry disability index (ODI), low back outcome score, visual analogue score and shuttle walking test were administered at baseline, 4, 10 and 16 weeks.
    Summary · context
    Forty patients with symptoms of neurogenic claudication and MRI proven lumbar spinal stenosis were randomly assigned either nasal salmon calcitonin or placebo nasal spray to use for 4 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with lumbar spinal stenosis, final ODI improved by 3.7 points in the initial calcitonin group versus 3.8 with initial placebo (P = 0.44).

    In plain wordsIn patients with spinal stenosis, final disability improvement did not differ significantly between the initial calcitonin and placebo groups.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeODI at trial end
    Study

    n = 40

    Comparator
    Initially assigned placebo nasal spray, before the later calcitonin treatment phase
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · nasalAs given in this study (human).

    Measurements

    ODI improvement
    3.7 points
    initial calcitonin
    ODI improvement
    3.8 points
    initial placebo
    P value
    0.44
    between groups

    Source sentences

    Summary
    At the end of the trial the ODI had improved by a mean of 3.7 points in the calcitonin group and 3.8 points in the placebo group (P = 0.44).
    2 context sentences
    Summary · context
    This was followed by a 'washout' period of 6 weeks, and subsequent treatment with 6 weeks of nasal salmon calcitonin.
    Summary · context
    Forty patients with symptoms of neurogenic claudication and MRI proven lumbar spinal stenosis were randomly assigned either nasal salmon calcitonin or placebo nasal spray to use for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.